Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy.

Autor: Luginbuehl V; Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Grueental, P.O.X. 335, CH-8820 Waedenswil, Switzerland., Meier N; Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Grueental, P.O.X. 335, CH-8820 Waedenswil, Switzerland., Kovar K; Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Grueental, P.O.X. 335, CH-8820 Waedenswil, Switzerland., Rohrer J; Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Grueental, P.O.X. 335, CH-8820 Waedenswil, Switzerland. Electronic address: roja@zhaw.ch.
Jazyk: angličtina
Zdroj: Biotechnology advances [Biotechnol Adv] 2018 May - Jun; Vol. 36 (3), pp. 613-623. Date of Electronic Publication: 2018 Feb 09.
DOI: 10.1016/j.biotechadv.2018.02.005
Abstrakt: A treasure trove of intracellular cancer drug targets remains hidden behind cell membranes. However, engineered pathogen-derived toxins such as Shiga toxins can deliver small or macromolecular drugs to specific intracellular organelles. After binding to ganglioglobotriaosylceramide (Gb3, CD77), the non-toxic subunit B (StxB) of the Shiga-holotoxin is endocytosed and delivers its payload by a unique retrograde trafficking pathway via the endoplasmic reticulum to the cytosol. This review provides an overview of biomedical applications of StxB-based drug delivery systems in targeted cancer diagnosis and therapy. Biotechnological production of the Stx-material is discussed from the perspective of developing efficacious and safe therapeutics.
(Copyright © 2018. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: